tesamorelin dosage visceral fat: Frequently asked questions

No. Doses above 2mg increase glucose intolerance and side effects without reliably improving fat loss. Non-response at week 12 indicates metabolic resistance, not insufficient dosing. Check thyroid function (TSH, free T4) and insulin sensitivity (fasting insulin, HOMA-IR). Untreated hypothyroidism or severe insulin resistance block tesamorelin's lipolytic signaling. Address those conditions first; raising the peptide dose compounds the glucose problem without solving the underlying metabolic block.

Not immediately, but intervention is required. First, confirm the elevation with a repeat fasting glucose test within 3–5 days. If confirmed, add metformin 500mg daily with dinner to improve insulin sensitivity, or reduce tesamorelin to 1.4mg daily. Recheck fasting glucose in 2 weeks. If glucose exceeds 126 mg/dL on two separate tests or HbA1c rises above 6.5%, discontinue tesamorelin and consult your prescribing physician. The metabolic cost outweighs the VAT reduction benefit at that threshold.

No. Never double-dose to compensate for a missed injection. Resume your normal 2mg dose the following evening and continue the regular schedule. Tesamorelin's mechanism relies on consistent pulsatile GH stimulation; doubling the dose creates a supraphysiologic GH spike that increases hyperglycemia risk and fluid retention without improving VAT reduction. Missing 1–2 doses per month has minimal impact on overall efficacy as long as the pattern isn't chronic.

Reduce your dose to 1.5mg daily for two weeks, then attempt to re-escalate to 2mg if symptoms resolve. Arthralgias occur in 5–8% of patients at 2mg daily and are caused by transient fluid retention in joint spaces as IGF-1 levels rise. The effect is self-limiting in most cases. Symptoms peak during weeks 2–4 and resolve by week 6–8 as the body adjusts to elevated IGF-1. If pain persists beyond eight weeks or worsens over time, discontinue tesamorelin and consult your supervising physician. Persistent arthralgias may indicate underlying inflammatory arthritis unmasked by GH stimulation rather than a direct peptide side effect.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your scheduled injection time, then resume your regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and continue with your next scheduled injection. Do not double-dose to compensate. Doubling doses does not produce twice the GH pulse; it saturates GHRH receptors without additional benefit while increasing the risk of arthralgias and injection site reactions. Missing occasional doses during the first month of treatment may slow initial VAT reduction but does not eliminate cumulative benefit if consistency is restored.

Discard the vial if it remained at room temperature (above 8°C) for more than 8 hours. Peptide stability at ambient temperature is limited to 72 hours maximum under controlled conditions, but that assumes consistent room temperature (20–22°C). Not fluctuating household conditions where temperatures may exceed 25°C. Visual inspection is unreliable: degraded tesamorelin remains a clear, colourless solution indistinguishable from active peptide. Injecting degraded peptide will not cause acute harm, but it delivers zero therapeutic effect. Essentially an expensive saline injection. Replace the vial rather than risk wasting weeks of a protocol on inactive compound.